BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 22561517)

  • 1. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
    Guichard C; Amaddeo G; Imbeaud S; Ladeiro Y; Pelletier L; Maad IB; Calderaro J; Bioulac-Sage P; Letexier M; Degos F; Clément B; Balabaud C; Chevet E; Laurent A; Couchy G; Letouzé E; Calvo F; Zucman-Rossi J
    Nat Genet; 2012 May; 44(6):694-8. PubMed ID: 22561517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
    Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
    World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
    Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G
    Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
    Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
    BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations.
    Vilarinho S; Erson-Omay EZ; Harmanci AS; Morotti R; Carrion-Grant G; Baranoski J; Knisely AS; Ekong U; Emre S; Yasuno K; Bilguvar K; Günel M
    J Hepatol; 2014 Nov; 61(5):1178-83. PubMed ID: 25016225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
    Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
    Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
    Schaeffer S; Gupta B; Calatayud AL; Calderaro J; Caruso S; Hirsch TZ; Pelletier L; Zucman-Rossi J; Rebouissou S
    J Hepatol; 2023 Sep; 79(3):704-716. PubMed ID: 37201672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.
    Chan AW; Zhang Z; Chong CC; Tin EK; Chow C; Wong N
    J Pathol; 2019 Oct; 249(2):166-172. PubMed ID: 31168847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse modes of genomic alteration in hepatocellular carcinoma.
    Jhunjhunwala S; Jiang Z; Stawiski EW; Gnad F; Liu J; Mayba O; Du P; Diao J; Johnson S; Wong KF; Gao Z; Li Y; Wu TD; Kapadia SB; Modrusan Z; French DM; Luk JM; Seshagiri S; Zhang Z
    Genome Biol; 2014 Aug; 15(8):436. PubMed ID: 25159915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
    Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
    Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy.
    Shen Y; Zheng X; Qian Y; Liu M; Nian Z; Cui Q; Zhou Y; Fu B; Sun R; Tian Z; Wei H
    Cancer Sci; 2023 Jun; 114(6):2386-2399. PubMed ID: 36919759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.